This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Feb 28;385(9970):771.

doi: 10.1016/S0140-6736(15)60432-9.

Alemtuzumab induction therapy in kidney transplantation - Authors' reply

Richard Haynes¹, Colin Baigent², Martin J Landray², Paul Harden³, Peter Friend⁴

Affiliations

Affiliations

¹ Clinical Trial Service Unit, and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK; Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK. Electronic address: richard.haynes@ctsu.ox.ac.uk.
² Clinical Trial Service Unit, and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
³ Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK.
⁴ Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

PMID: 25752173
DOI: 10.1016/S0140-6736(15)60432-9

Comment

Alemtuzumab induction therapy in kidney transplantation - Authors' reply

Richard Haynes et al. Lancet. 2015.

. 2015 Feb 28;385(9970):771.

doi: 10.1016/S0140-6736(15)60432-9.

Authors

Richard Haynes¹, Colin Baigent², Martin J Landray², Paul Harden³, Peter Friend⁴

Affiliations

¹ Clinical Trial Service Unit, and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK; Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK. Electronic address: richard.haynes@ctsu.ox.ac.uk.
² Clinical Trial Service Unit, and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
³ Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK.
⁴ Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

PMID: 25752173
DOI: 10.1016/S0140-6736(15)60432-9

No abstract available

PubMed Disclaimer

Comment on

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
3C Study Collaborative Group; Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray MJ, Baigent C, Friend PJ. 3C Study Collaborative Group, et al. Lancet. 2014 Nov 8;384(9955):1684-90. doi: 10.1016/S0140-6736(14)61095-3. Epub 2014 Jul 28. Lancet. 2014. PMID: 25078310 Clinical Trial.
Alemtuzumab induction therapy in kidney transplantation.
Berghofen A, Singer T, Krüger B, Krämer BK, Benck U. Berghofen A, et al. Lancet. 2015 Feb 28;385(9970):770-1. doi: 10.1016/S0140-6736(15)60431-7. Lancet. 2015. PMID: 25752170 No abstract available.
Alemtuzumab induction therapy in kidney transplantation.
Dhaun N, Kluth DC. Dhaun N, et al. Lancet. 2015 Feb 28;385(9970):770. doi: 10.1016/S0140-6736(15)60430-5. Lancet. 2015. PMID: 25752171 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science